Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Zusammenfassung

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

Eignung

Studiendesign

Endpunkte

1. Primärer Endpunkt

   Percent Change from Baseline in Body Weight

   Percent Change from Baseline in Body Weight

   Zeitrahmen Baseline, Week 64

2. Primärer Endpunkt

   Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score

   Change from Baseline in the WOMAC Pain Subscale Score

   Zeitrahmen Baseline, Week 64

3. Sekundärer Endpunkt

   Change from Baseline in Systolic Blood Pressure (SBP)

   Change from Baseline in SBP

   Zeitrahmen Baseline, Week 64

4. Sekundärer Endpunkt

   Percent Change from Baseline in Triglycerides

   Percent Change in Baseline in Triglycerides

   Zeitrahmen Baseline, Week 64

5. Sekundärer Endpunkt

   Change from Baseline in Short Form-36 (SF-36 v2) Acute Form Physical Functioning Domain Score

   Change from Baseline in SF-36 v2 Score

   Zeitrahmen Baseline, Week 64

6. Sekundärer Endpunkt

   Percent Change from Baseline in High Sensitivity, C-reactive Protein (hsCRP)

   Percent Change from Baseline in hsCRP

   Zeitrahmen Baseline, Week 64

7. Sekundärer Endpunkt

   Change from Baseline in the WOMAC Physical Function Subscale Score

   Change from Baseline in the WOMAC Physical Function Subscale Score

   Zeitrahmen Baseline, Week 40, Week 64

8. Sekundärer Endpunkt

   Change from Baseline WOMAC Pain Subscale Score

   Change from Baseline WOMAC Pain Subscale Score

   Zeitrahmen Baseline, Week 40

9. Sekundärer Endpunkt

   Change from Baseline in Distance Walked During the 6-Minute Walk Test

   Change from Baseline in Distance Walked During the 6-Minute Walk Test

   Zeitrahmen Baseline, Week 64

10. Sekundärer Endpunkt

    Change from Baseline in Body Mass Index (BMI)

    Change from Baseline in BMI

    Zeitrahmen Baseline, Week 64

11. Sekundärer Endpunkt

    Change in Medication Use

    Change in Medication Use

    Zeitrahmen Baseline, Week 64

12. Sekundärer Endpunkt

    Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score

    Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score

    Zeitrahmen Baseline, Week 64

13. Sekundärer Endpunkt

    Change from Baseline in Health Status EQ-5D-5L Health State Utility

    Change from Baseline in Health Status EQ-5D-5L Health State Utility

    Zeitrahmen Baseline, Week 64

14. Sekundärer Endpunkt

    Percent Change from Baseline in Fasting Insulin

    Percent Change from Baseline in Fasting Insulin

    Zeitrahmen Baseline, Week 64

15. Sekundärer Endpunkt

    Percent Change from Baseline in Total Cholesterol

    Percent Change from Baseline in Total Cholesterol

    Zeitrahmen Baseline, Week 64

16. Sekundärer Endpunkt

    Change from Baseline in Waist Circumference

    Change from Baseline in Waist Circumference

    Zeitrahmen Baseline, Week 64

17. Sekundärer Endpunkt

    Percent Change from Baseline in Hemoglobin A1c (HbA1c)

    Percent Change from Baseline in HbA1c

    Zeitrahmen Baseline, Week 64

18. Sekundärer Endpunkt

    Change from Baseline in WOMAC Stiffness Subscale Score

    Change from Baseline in WOMAC Stiffness Subscale Score

    Zeitrahmen Baseline, Week 64

19. Sekundärer Endpunkt

    Change from Baseline in WOMAC Total Score

    Change from Baseline in WOMAC Total Score

    Zeitrahmen Baseline, Week 64

20. Sekundärer Endpunkt

    Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Pain

    Achievement of Improved Categorical Shift in PGIS - Target Knee Pain

    Zeitrahmen Baseline, Week 64

21. Sekundärer Endpunkt

    Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Function

    Achievement of Improved Categorical Shift in PGIS - Target Knee Function

    Zeitrahmen Baseline, Week 64

22. Sekundärer Endpunkt

    Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS) Score

    Change from Baseline in API-NRS Score

    Zeitrahmen Baseline, Week 64

23. Sekundärer Endpunkt

    Change from Baseline in Worst Pain Intensity Numeric Rating Scale (WPI-NRS) Score

    Change from Baseline in WPI-NRS Score

    Zeitrahmen Baseline, Week 64

24. Sekundärer Endpunkt

    Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax, ss)

    PK: Cmax, ss

    Zeitrahmen Baseline through Week 64

25. Sekundärer Endpunkt

    PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-T)ss)

    PK: AUC(0-T)ss

    Zeitrahmen Baseline through Week 64

26. Sekundärer Endpunkt

    Number of Participants with Allowed Concomitant Pain Medication

    Number of Participants with Allowed Concomitant Pain Medication

    Zeitrahmen Baseline, Week 64

Daten

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

126 Studienzentren rekrutieren

102 weitere Studienzentren sind im Registereintrag aufgeführt.

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

1. 6. August 2026

   Studienzentrum entfernt

   9 sites removed (152 total)

   161 → 152